LeadCare II
Commercial- Indications
- Lead poisoning
Company intelligence / Profile preview
Magellan Diagnostics pioneered point-of-care and laboratory-based blood lead testing devices using ASV technology. Their products—LeadCare II, LeadCare Ultra, and LeadCare Plus—are widely used for detecting lead exposure in children and adults. The company faced regulatory scrutiny due to device malfunctions affecting venous sample results between 2013–2017 but has since remediated these issues. Their systems remain the leading CLIA-waived solutions for blood lead level testing in the U.S.[1][2][5][6]
A third-generation platform with additional pediatric tests was planned as of acquisition but not yet commercialized[5].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Magellan Diagnostics.